TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17486281
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of tadalafil on demand
Study: 17486281
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of tadalafil three times per week
Study: 9801927
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (12,500 U, subcutaneously daily) plus antianginal treatment
Study: 1550410
Drug: Lornoxicam 12
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 12 mg daily
Study: 25773712
Drug: Lixisenatide 20
Normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 20 µg
Study: 24561125
Drug: Liraglutide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.2 mg and 1.8 mg
Study: 23578669
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment (endovascular surgery, coiling, clipping) for UIAs larger than 5 mm
Study: 21274557
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sildenafil p.o.
Study: 21274557
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sildenafil p.o.
Study: 21274557
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg iloprost inhalation
Study: 19248129
Drug: Anakinra 50
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 50 mg
Study: 19248129
Drug: Anakinra 150
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 150 mg
Study: 9041991
Drug: IV IgG
Normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV IgG (Polyglobin, n = 14, total dosage: 18 mL/kg)
Study: 9041991
Drug: IV IgGMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV IgGMA (Pentaglobin, n = 13, total dosage: 15 mL/kg)
Study: 27401564
Drug: Intravenous or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous or oral fluconazole at 6 mg/kg of body weight twice weekly
Study: 25762749
Drug: Varenicline (VAR)
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline (VAR) tablets and placebo patches
Study: 25762749
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets and nicotine patches
Study: 21610201
Drug: TAK-875 (25-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 (25-800 mg)
Study: 19880786
Drug: Maintain testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintain testosterone and estradiol at eugonadal levels for young men (GnRH agonist + testosterone gel)
Study: 19880786
Drug: Block testosterone's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Block testosterone's conversion to estradiol (GnRH agonist + testosterone gel + aromatase inhibitor)
Study: 19880786
Drug: Induce hypogonadism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induce hypogonadism (GnRH agonist alone)
Study: 17980667
Drug: Minocycline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (up to 400 mg/day for 9 months)
Study: 15642073
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin XR 2000 mg once daily
Study: 15966755
Drug: Metformin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin IR 1000 mg twice daily
Study: 12483717
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of MRA
Study: 12483717
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of MRA
Study: 12483717
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg and 10 mg/kg of MRA
Study: 10488265
Drug: Intradermal bacteriostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal bacteriostatic 0.9% sodium chloride containing the preservative benzyl alcohol
Study: 10488265
Drug: Intradermal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal lidocaine hydrochloride 1%
Study: 24763890
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream containing 0.5% Aloe vera juice powder applied 3 times per day for 6 weeks
Study: 16268392
Drug: Ranir Whitening
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranir Whitening Wraps (WW2) used twice a day
Study: 16268392
Drug: Crest Whitestrips
Normalized name: Crest
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crest Whitestrips Premium (WP2) used twice a day
Study: 12162472
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg morphine alone
Study: 12162472
Drug: 15-minute TEAS
Normalized name: tea tree oil 0.15 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-minute TEAS plus morphine
Study: 9861593
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of magnesium (as MgO)
Study: 7635854
Drug: Clomipramine or
Normalized name: clomipramine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine or Fluoxetine
Study: 31685913
Drug: Modified aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified aerobic training with a load on the lower limbs (MG)
Study: 26856247
Drug: Prednisone (PD)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (PD) treatment over 4.3 years
Study: 26856247
Drug: High-dose anti-metabolite
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose anti-metabolite treatment arm
Study: 23386641
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 4800 IU daily
Study: 23386641
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 800 IU daily
Study: 23386641
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements to maintain total calcium intake of 1200-1400 mg/d
Study: 19586229
Drug: Oral methadone-naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone-naloxone in a 50:1 ratio
Study: 19586229
Drug: Intramuscular methadone-naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular methadone-naloxone in a 50:1 ratio
Study: 8006397
Drug: 4-week course
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week course of prednisolone followed by 2 weeks of no treatment and then a 12-week course of human lymphoblastoid interferon, 4 to 6 MU/m2 intramuscularly
Study: 2920071
Drug: 1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg of alcohol (12.5%, v/v)
Study: 29241576
Drug: 1 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 300 mL plum juice
Study: 29241576
Drug: 3 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 × 100 mL plum juice
Study: 25487567
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg · kg(‐1) (Group D1)
Study: 25487567
Drug: Dexmedetomidine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 2 μg · kg(‐1) (Group D2)
Study: 19532851
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (NTG) patch
Study: 16214329
Drug: PUFA n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA n-3 supplementation (3.6 g daily for 3 months)
Study: 11425671
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) therapy
Study: 9260214
Drug: Schwarz strain
Normalized name: measles virus vaccine live, attenuated Schwarz strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz strain measles vaccine (SWMV)
Study: 9260214
Drug: Edmoston-Zagreb strain
Normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmoston-Zagreb strain measles vaccine (EZMV)
Study: 8033606
Drug: Retinoic acid
Normalized name: Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retinoic acid (RA) alone at an oral dose of 45-60 mg/m2/d
Study: 8033606
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (RA and chemotherapy)
Study: 8033606
Drug: RA as
Normalized name: Flora Assist Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA as continuation therapy (Group A)
Study: 8033606
Drug: RA and
Normalized name: Cascara and senna only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA and chemotherapy alternately (Group C)
Study: 3885963
Drug: Flupirtine 100
Normalized name: flupirtine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine 100 mg capsules
Study: 3885963
Drug: Pentazocine 50
Normalized name: pentazocine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 50 mg capsules
Study: 25156398
Drug: Attention training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention training towards positive stimuli (ATP) combined with one-session treatment (OST)
Study: 25156398
Drug: Attention training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention training control (ATC) combined with one-session treatment (OST)
Study: 20584565
Drug: 28 g
Normalized name: SM Syringe 28 g, 0.5cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 g acetogenic fibers (acacia gum and pectin)
Study: 20584565
Drug: Fiber treatment
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber treatment
Study: 15931646
Drug: 20.8 mg
Normalized name: sulfur 20.8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20.8 mg of sodium iron gluconate at the end of each dialysis session (Group A)
Study: 15931646
Drug: 62.5 mg
Normalized name: quinine 162.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 62.5 mg of sodium iron gluconate only at the end of the 1st dialysis session of the week (Group B)
Study: 2580171
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg orally (acute and fasting)
Study: 2580171
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg orally (with concomitant food intake)
Study: 2580171
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg orally (without concomitant food intake)
Study: 2580171
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg three times a day for 4-5 weeks (chronic treatment)
Study: 2580171
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg (twice daily)
Study: 26400628
Drug: Topical antifungal
Normalized name: Imidazole and triazole derivatives, topical antifungals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antifungal treatment + oral antifungal
Study: 26400628
Drug: Topical antifungal
Normalized name: Imidazole and triazole derivatives, topical antifungals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antifungal treatment + ICAMB + oral antifungal
Study: 26400628
Drug: Topical antifungal
Normalized name: Imidazole and triazole derivatives, topical antifungals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antifungal treatment + drainage of hypopyon + ICAMB + oral antifungal
Study: 21162931
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg oral midazolam (Group I)
Study: 18519835
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) consisting of seven standardized techniques for 20 minutes.
Study: 18519835
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (light touch applied to the same anatomic regions for 20 minutes).
Study: 15741580
Drug: BIS-blinded group
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS-blinded group (single dose)
Study: 15741580
Drug: BIS-unblinded group
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS-unblinded group (single dose)
Study: 15741580
Drug: BIS-blinded group
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS-blinded group (multiple doses)
Study: 15741580
Drug: BIS-unblinded group
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS-unblinded group (multiple doses)
Study: 10566703
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.i.d. for 12 weeks
Study: 9012256
Drug: lerivon (L)
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lerivon (L) for 1 month
Study: 25434303
Drug: Matched unrelated
Normalized name: Latanoprost related compound e
DrugBank: Latanoprost acid (DB19360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched unrelated hematopoietic cell transplantation (HCT) in first remission for patients with FLT3-ITD allelic ratio >0.8, poor day +15 marrow blast clearance, and adverse karyotypes; allogeneic HCT in high-risk AML performed in aplasia after induction chemotherapy
Study: 23504636
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg QD with PegIFN/RBV (48 weeks)
Study: 23504636
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg QD without lead-in (48 weeks)
Study: 23504636
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg BID with lead-in (48 weeks)
Study: 23504636
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg QD/LI (rerandomized to 48 weeks treatment)
Study: 23504636
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg QD/LI, 240 mg QD, and 240 mg BID/LI (adverse events)
Study: 23504636
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg BID
Study: 19136900
Drug: Fluvastatin (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40-80 mg daily)
Study: 12948282
Drug: α-tocopherol supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-tocopherol supplementation (50 mg/day for five to eight years)
Study: 7780491
Drug: dexfenfluramine (dF)
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexfenfluramine (dF) 30 mg/d
Study: 2180388
Drug: Daily mud
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mud packs
Study: 2180388
Drug: Daily hot
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily hot sulphur baths
Study: 2180388
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mud packs and hot sulphur baths
Study: 7462801
Drug: cholestyramine (8g)
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cholestyramine (8g) administered 30 min prior to test
Study: 17570410
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg daily from postoperative days 1 to 90
Study: 17570410
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg per day as needed
Study: 11199942
Drug: Olanzapine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (daily doses ranging from 2.5 to 17.5 mg/day for up to 6 weeks)
Study: 11199942
Drug: Haloperidol (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (exact dosage and duration not specified)
Study: 11199942
Drug: Placebo (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (exact dosage and duration not specified)
Study: 8006647
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (Epilim EC enteric coated 200 mg tablets twice daily)
Study: 8006647
Drug: Carbamazepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (100 mg twice daily increasing to 200 mg twice daily in week 2)
Study: 19160404
Drug: Topical amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical amphotericin B
Study: 14970005
Drug: BCAA mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA mixture intake (0, 20, 30, 50, 60, 70, 90, 110, and 130 mg.kg(‐1).day(‐1))
Study: 9854277
Drug: Supervised fitness
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised fitness training under bright light (2500-4000 lx) 2-3 times weekly for 8 weeks
Study: 9854277
Drug: Supervised fitness
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised fitness training under ordinary light (400-600 lx) 2-3 times weekly for 8 weeks
Study: 8582955
Drug: Cabergoline 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 1.0 mg oral administration for inhibition of puerperal lactation
Study: 8582955
Drug: Cabergoline 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 1.0 mg (0.25 mg twice daily for 2 days) for suppression of established lactation
Study: 8582955
Drug: Cabergoline 1-2
Normalized name: cabergoline 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 1-2 mg weekly doses (twice weekly schedule) for hyperprolactinaemic amenorrhoea
Study: 2121406
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 g with five-minute tourniquet inflation
Study: 2121406
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 g with two-minute tourniquet inflation
Study: 2121406
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 g with one-minute tourniquet inflation
Study: 28668719
Drug: Rapid acting
Normalized name: insulin inhalation, rapid acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid acting insulin analog (RAIA)
Study: 28668719
Drug: Nurse perceptions
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse perceptions of RAIA dosing
Study: 28668719
Drug: Nurse perceptions
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse perceptions of electronic dosing calculator and patient reminder
Study: 19167693
Drug: Desvenlafaxine 100
Normalized name: desvenlafaxine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 100 mg
Study: 19167693
Drug: Desvenlafaxine 150
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine 150 mg
Study: 9638033
Drug: Caffeine (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (4.5 mg caffeine/kg fat-free mass)
Study: 8206809
Drug: Sulpiride 150
Normalized name: (±)-sulpiride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride 150 mg
Study: 8206809
Drug: Sulpiride 300
Normalized name: (±)-sulpiride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride 300 mg
Study: 4885615
Drug: Dipyridamole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (400 mg daily for 14 months, then 800 mg daily for 11 months)
Study: 30365461
Drug: Laser-assisted corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-assisted corticosteroid delivery (topical triamcinolone acetonide 20 mg/mL)
Study: 30365461
Drug: Laser-assisted 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-assisted 5-fluorouracil delivery (topical 5-fluorouracil 50 mg/mL)
Study: 23244536
Drug: 1.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/d c9, t11 CLA for 16 weeks
Study: 23244536
Drug: 3.0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g/d c9, t11 CLA for 16 weeks
Study: 19032576
Drug: ondansetron 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 0.5 mg/d
Study: 19032576
Drug: sertraline 200
Normalized name: sertraline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertraline 200 mg/d
Study: 17522585
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) 70 microg/kg administered intravenously
Study: 2649461
Drug: Topical infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical infusion of metronidazole solution
Study: 2649461
Drug: Treatment without
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment without metronidazole
Study: 31952545
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of zoledronic acid to consolidation chemotherapy
Study: 20439056
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (average 10 sessions)
Study: 15824361
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 1,300 mg/day
Study: 12066083
Drug: Subcutaneous stitch
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous stitch closure
Study: 12066083
Drug: Subcutaneous drain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous drain placement
Study: 10910540
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (RI) infusion (n = 20); ratio of infusion glucose to regular insulin was 10‐15 gm glucose to 1 unit RI, glucose infusion rate maintained at least 6 mg/Kg/min.